中文
About Us
Corporate Overview
Sr. Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filings
News
2019
2018
2017
2016
2015
2014
Careers
2019
2018
2017
2016
2015
2014
Ascletis Received IND Approval for its NASH Drug
2019-08-28
Ascletis Opens Clinical Development Shanghai Center
2019-08-12
Ascletis’ Strategic Partner 3-V Biosciences Announced its Name Change and Financing Status
2019-08-06
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
2019-08-05
Ascletis to Attend Goldman Sachs China Healthcare Corporate Day 2019
2019-06-24
«
1
2
3
4
»
